{"analyses":[{"ciLowerLimit":"10.74","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"16.92","groupDescription":"QLQ-C30 Global QoL: Analysis was from a repeated measures mixed-effects model with an intercept term, treatment, treatment-by-time interaction, and baseline EORTC QLQ-C30 subscale baseline score (intercept and time from first dose are included as random effects).","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","paramType":"Mean Difference (Net)","paramValue":"13.8303","statisticalMethod":"Mixed Models Analysis"},{"ciLowerLimit":"0.60","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"6.11","groupDescription":"QLQ-C30 cognitive functioning: Analysis was from a repeated measures mixed-effects model with an intercept term, treatment, treatment-by-time interaction, and baseline EORTC QLQ-C30 subscale baseline score (intercept and time from first dose are included as random effects).","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0170","paramType":"Mean Difference (Net)","paramValue":"3.3532","statisticalMethod":"Mixed Models Analysis"},{"ciLowerLimit":"4.57","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"10.46","groupDescription":"QLQ-C30 emotional functioning: Analysis was from a repeated measures mixed-effects model with an intercept term, treatment, treatment-by-time interaction, and baseline EORTC QLQ-C30 subscale baseline score (intercept and time from first dose are included as random effects).","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","paramType":"Mean Difference (Net)","paramValue":"7.5165","statisticalMethod":"Mixed Models Analysis"},{"ciLowerLimit":"7.48","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"13.32","groupDescription":"QLQ-C30 physical functioning: Analysis was from a repeated measures mixed-effects model with an intercept term, treatment, treatment-by-time interaction, and baseline EORTC QLQ-C30 subscale baseline score (intercept and time from first dose are included as random effects).","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","paramType":"Mean Difference (Net)","paramValue":"10.4035","statisticalMethod":"Mixed Models Analysis"},{"ciLowerLimit":"11.29","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"19.81","groupDescription":"QLQ-C30 role functioning: Analysis was from a repeated measures mixed-effects model with an intercept term, treatment, treatment-by-time interaction, and baseline EORTC QLQ-C30 subscale baseline score (intercept and time from first dose are included as random effects).","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","paramType":"Mean Difference (Net)","paramValue":"15.5513","statisticalMethod":"Mixed Models Analysis"},{"ciLowerLimit":"4.69","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"12.84","groupDescription":"QLQ-C30 social functioning: Analysis was from a repeated measures mixed-effects model with an intercept term, treatment, treatment-by-time interaction, and baseline EORTC QLQ-C30 subscale baseline score (intercept and time from first dose are included as random effects).","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","paramType":"Mean Difference (Net)","paramValue":"8.7641","statisticalMethod":"Mixed Models Analysis"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.92","upperLimit":"8.05","value":"5.9815"},{"groupId":"OG001","lowerLimit":"-10.15","upperLimit":"-5.55","value":"-7.8488"}]}],"title":"QLQ-C30 Global QoL"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.66","upperLimit":"3.03","value":"1.1836"},{"groupId":"OG001","lowerLimit":"-4.21","upperLimit":"-0.13","value":"-2.1696"}]}],"title":"QLQ-C30 Cognitive Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.77","upperLimit":"10.72","value":"8.7431"},{"groupId":"OG001","lowerLimit":"-0.95","upperLimit":"3.40","value":"1.2266"}]}],"title":"QLQ-C30 Emotional Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.94","upperLimit":"7.93","value":"5.9370"},{"groupId":"OG001","lowerLimit":"-6.59","upperLimit":"-2.34","value":"-4.4664"}]}],"title":"QLQ-C30 Physical Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.92","upperLimit":"7.71","value":"4.8122"},{"groupId":"OG001","lowerLimit":"-13.87","upperLimit":"-7.61","value":"-10.7391"}]}],"title":"QLQ-C30 Role Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.60","upperLimit":"7.15","value":"4.3790"},{"groupId":"OG001","lowerLimit":"-7.37","upperLimit":"-1.40","value":"-4.3851"}]}],"title":"QLQ-C30 Social Functioning"}],"denoms":[{"counts":[{"groupId":"OG000","value":"166"},{"groupId":"OG001","value":"163"}],"units":"Participants"}],"description":"EORTC QLQ-C30: included 5 functional scales (physical, role, cognitive, emotional and social), global health status/global quality of life scale, 3 symptom scales (fatigue, pain, nausea and vomiting), 6 single items that assess the additional symptoms (dyspnea, appetite loss, sleep disturbance, constipation, diarrhea) and financial difficulties. All scales and single-item measures range from 0 to 100. A high score for a functional scale represents a high/healthy level of functioning, for the global health status/QoL represents a high QoL (better participant state), and for a symptom scale/item represents a high level of symptoms/problems (worse participant state).","dispersionType":"95% Confidence Interval","groups":[{"description":"Crizotinib 250 mg capsule, orally twice daily was administered in treatment cycle of 21 days. Participants could continue crizotinib treatment beyond the time of RECIST v1.1 defined PD, as determined by IRR, at the discretion of the investigator if the participant was perceived to be experiencing clinical benefit.","id":"OG000","title":"Crizotinib"},{"description":"Standard doses of chemotherapy (pemetrexed/cisplatin or pemetrexed/carboplatin) were administered intravenously on Day 1 of each cycle for a maximum of 6 cycles. Pemetrexed 500 mg per meter square (m)\\^2 IV infusion according to standard of care was administered over 10 min; either cisplatin 75 mg/m\\^2 IV infusion was administered approximately 30 min after the end of the pemetrexed infusion or carboplatin was administered at a dose calculated to produce an AUC of 5 or 6 mg\\*min/mL, approximately 30 min after end of pemetrexed infusion.","id":"OG001","title":"Chemotherapy"}],"paramType":"MEAN","populationDescription":"The PRO evaluable population included all participants from the FA population who completed a baseline and at least 1 postbaseline PRO assessment prior to crossover to crizotinib or end of randomized study treatment.","reportingStatus":"POSTED","timeFrame":"Baseline, From Cycle 1 Day 1 up to end of study treatment or crossover to crizotinib arm (up to 35 months)","title":"Change From Baseline in Functioning and Global Quality of Life (QOL) as Assessed by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30)","type":"SECONDARY","unitOfMeasure":"units on a scale"}